SKYE SKYE
Company Profile ↓Company Overview
SKYE (SKYE) is a publicly traded company listed on with a market capitalization of $18.69M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -83.53% |
| 6 Months: | -37.73% |
| 3 Months: | -35.95% |
| 1 Month: | -20.10% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)32.53 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 88.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Apr 2014 | Jun 2014 | Jul 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.76M | 18.24M | 13.26M | 14.90M | 12.67M |
| Operating Income | -13.43K | -142.92K | 4.05K | -857.61K | -909.83K | -1.36M | -896.29K | -1.22M | -1.48M | -856.15K | -1.38M | -730.93K | -761.63K | -1.25M | -1.08M | -1.05M | -1.52M | -1.77M | -1.50M | -2.21M | -1.22M | -1.54M | -1.74M | -1.83M | -1.82M | -2.89M | -3.22M | -2.92M | -3.10M | -2.84M | -24.71M | -6.15M | -8.41M | -4.97M | - | -11.76M | -18.24M | -13.26M | -14.90M | -12.67M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.92M | -17.43M | -12.58M | -14.26M | -12.33M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.45K | 0 | 0 | 0 | 2.20K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.10M | -17.62M | -12.75M | -14.44M | -12.51M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.00K | 3.40K | 0 | 0 | 0 |
| Net Income | -13.51K | -142.92K | 7.76K | -858.52K | -910.23K | -2.06M | -1.18M | -1.69M | 573.09K | -945.27K | -1.28M | -702.76K | -480.13K | -8.21M | -2.66M | -2.10M | -14.77M | 15.91M | -4.93M | -2.34M | -1.42M | -1.30M | -2.16M | -2.02M | -1.82M | -3.04M | -3.42M | -3.13M | -5.17M | -3.11M | -24.95M | -5.02M | -7.90M | -3.90M | - | -11.10M | -17.62M | -12.75M | -14.44M | -12.51M |
| Diluted EPS | - | - | - | - | - | -0.13 | - | - | 0.03 | -0.05 | -0.09 | -0.02 | -0.02 | -0.09 | -0.02 | -0.02 | -0.11 | 0.08 | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 | -1.58 | -1.37 | -0.80 | -3.17 | -0.18 | -0.20 | -0.10 | - | -0.28 | -0.44 | -0.32 | -0.36 | -0.32 |
| R&D Expense | - | - | - | 195.00K | 37.20K | 43.37K | 152.29K | 135.36K | 459.96K | 80.53K | 92.10K | 60.65K | 88.55K | 25.00K | - | 67.29K | 320.99K | 688.04K | 513.00K | 799.61K | 428.53K | 346.22K | 609.66K | 880.67K | 327.73K | 1.27M | 1.43M | 1.78M | 1.18M | 1.79M | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2012 | Oct 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 12.11M | 13.67M | 36.43M | 58.16M |
| Operating Income | 4.12K | -7.24K | -120.40K | -2.73M | -4.32M | -4.47M | -3.86M | -4.69M | -6.63M | -6.29M | - | -12.11M | -13.67M | -36.43M | -58.16M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -18.70M | -36.62M | -25.29M | -55.20M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 663.77K | 897.21K | 967.60K | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -19.47M | -37.64M | -26.56M | -55.92M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 6.74K | 3.60K | 10.07K | 5.40K |
| Net Income | 4.51K | -3.78K | -120.40K | -2.73M | -4.84M | -3.18M | -3.09M | -19.19M | 1.05M | -6.56M | - | -19.48M | -37.64M | -26.57M | -55.92M |
| Diluted EPS | - | - | - | - | - | -0.17 | -0.11 | -0.16 | -0.05 | -0.03 | - | -8.77 | -5.37 | -0.73 | -1.41 |
| R&D Expense | - | - | - | 227.50K | 576.09K | 939.04K | 311.30K | 329.97K | 2.24M | 1.94M | 2.93M | 6.01M | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2011 | Oct 2012 | Dec 2012 | Oct 2013 | Dec 2013 | Sep 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 42.88K | - | 145.69K | - | - | 348.35K | 3.51M | 323.36K | 557.22K | 1.96M | 2.00M | 2.67M | - | 9.11M | 11.94M | 72.76M | 28.31M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.94M | 11.65M | 70.83M | 27.09M |
| Cash & Equivalents | 13.91K | 26.40K | - | 52.19K | - | 1.03M | 207.33K | 3.22M | 64.82K | 259.95K | 1.85M | - | - | - | 1.24M | 1.26M | 68.42M | 5.88M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.12K | 158.24K | 5.07K | 10.47K |
| Total Liabilities | - | 4.33K | - | 62.32K | 182.15K | - | 801.89K | 3.04M | 1.77M | 1.36M | 17.52M | 1.45M | 2.22M | - | 12.12M | 14.07M | 4.61M | 8.29M |
| Current Liabilities | - | 4.33K | - | 62.32K | 182.15K | - | 801.09K | 581.86K | 661.96K | 805.97K | 15.94M | 970.82K | 787.20K | - | 12.12M | 13.90M | 4.34M | 8.21M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.98M | 4.62M | 455.59K | 273.65K |
| Total Equity | 25.95K | 38.56K | -61.75K | 83.38K | -182.15K | - | -453.55K | -892.20K | -2.91M | -3.57M | -15.56M | 548.06K | 450.79K | - | -3.01M | -2.13M | 68.15M | 20.02M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.65M | 12.35M | 30.97M | 33.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -3.33M | -3.94M | -6.03M | -6.05M | - | -12.74M | -13.95M | -25.24M | -43.06M |
| Investing Cash Flow | - | - | - | - | -19.65K | -4.38K | - | -7.23K | - | 5.21M | 6.60M | -245.62K | -19.50M |
| Financing Cash Flow | - | - | - | - | 3.51M | 5.54M | 6.00M | 6.70M | - | -208.79K | 16.44M | 83.56M | 29.57K |
| Capital Expenditure | -49.12K | -23.26K | -1.98K | -11.12K | -19.65K | -4.38K | - | -7.23K | - | -28.06K | -12.55K | -1.60M | -6.31K |
| Free Cash Flow | - | - | - | - | -3.35M | -3.95M | - | -6.06M | - | -12.77M | -13.96M | -26.84M | -43.07M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -7.74M | 9.09M | 58.08M | -62.53M |
Ratios (Annual)
Figures in %.
| Metric | Oct 2012 | Oct 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 11.7% | -4.5% | 66.1% | 602.8% | 542.6% | 109.1% | 86.7% | 123.3% | 191.9% | -1,455.4% | - | 647.6% | 1,765.9% | -39.0% | -279.3% |
| ROCE % | 10.7% | -8.7% | - | 603.4% | -147.4% | 1,320.3% | 1,551.4% | 33.6% | -646.5% | -333.7% | - | 402.5% | 697.3% | -53.2% | -289.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SKYE
Skye Bioscience (NASDAQ: SKYE) shifts to Nasdaq Capital Market amid listing notices - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNR1ZIaEhMWG8tMmtiaFR5VnNDd3FGd0EzcW8wOE5CM2ZMckpnNGhNYjNpYm5mM29IUTVFclFzaHdsSnZ0OUdYOEFxZmJuOThnMU84aGpyUXQyUUdzdV83eWJibGFVWG93RjJPR2pTR2lpMVFuTHYtYmJvSXdLVFBteHg0LVU4c1ZEdjA5bn…
Skye’s shares crash down to earth on Phase II obesity loss - Clinical Trials Arena
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPQ2lIU0VYTHphRE40eWgtWkZkWjUzS2wtTXdjSUFKdDNXOUZfQUJ5TDMwZWZQRmVoUEUzQUp6elpTUXBRQnZidmk2eFlJOGMzaVVZNXZhWlRQNVRRRGNLZVkzQW0wRXBKTEJDckt1bzZaTmREVzJZbmZwVXByRGppMUVnSGZrMjZhTm1qUT…
Skye Bioscience, Inc. Revenue Breakdown – NASDAQ:SKYE - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFA5YlJEaWs0TWVLRm1KZXptNFFNQktLZjBrcDNMV1BHdTZaeTR1MFVTUzNJZV8tOTNqTy1INVgyQmo1cGtkQjNuT1BWU3M3V21DdUNTX1Z6T0RaRUU2bE5XdjJqdFNKeUNpcnBfNDh1MWNSWlVwTS1j?oc=5" target="_blank">Skye Bi…
Skye shares crash as obesity drug falls short in key study - biopharmadive.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPaC1SSi1STlI4WlBuOFZ5dEJWNl9HRXhpS0E3dWFWdGVqMldhZVp4ZFIyUnVnYzJqSTFIYmF4LS0zbXJzRG8xakQ2NVJsRmtrTC10aHFhcmV4ck9PUk5Fakg3M19TRFlUaDFPa0F4eGlYVWVCY3AxZ0VCNlpPQko3NG84UDNSMkpwdEl4eW…
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQQmctYXZ4eXFaTEhlelBJUlp0T3VxcXExYjc3bUZrcDlrQnhQdTFyczVFVU4wQXByUjZLMDZNODVtTFJYOGExOWFPWjJ4M2Ywd2ltX1NhX0xTSTdKSGR0Zk93OG5hZkFmRTJIMktPSERFV0tEOG1sYnpRS29NQ2k0VA?oc=5" target="_…
Skye Bioscience Treats First Patient in Nimacimab - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi5AJBVV95cUxOeDgxMVhnbmUyMlc2OU90TXRUUEhqaW40bzNhenNsVU5PQTR2eUN0ZVNjbnhMbWMtNWtRRDFicWRUNmN1M29Fc3h0bUNaVEdsLU5GbHBoNC0wVHhSMl9IT0lkOUZ0S0h4N1I4a0p0dHd4VVFxNmNMY1d0WHhoZWplLUVjVmQycXF4TkVsbU…
SKYE — Frequently Asked Questions
What is the current share price of SKYE?
As of 2026-08-05 17:25 PDT, SKYE trades at $0.56 on NASDAQ/NYSE. Its 52-week range is $0.56 to $4.75.
What is the market capitalisation of SKYE?
SKYE has a market capitalisation of $18.69M on NASDAQ/NYSE.
What is the P/E ratio of SKYE?
SKYE trades at a trailing price-to-earnings (P/E) ratio of -0.40. Its price-to-book (P/B) ratio is 0.93.
Is SKYE a good stock to buy?
This page provides a data-driven analysis of SKYE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.